Gege Gui (@GegeGui0) profile picture

Research Scientist at Virginia Tech FBRI Cancer Research Center

Washington, DC
Joined November 2019
Great talks today at #iwAL26 in Cambridge, MA from Drs @GegeGui0 and Sushree Sahoo. fbri.vtc.vt.edu/people-direc… @vt_dcarea @FralinBiomed
3
15
973
Genuinely excited to be finally able to fully share the first major output from the MEASURE consortium at #ASH25 #ASH2025 - the largest cohort of paired tumor and remission WGS from patients with AML meetings-api.hematology.org/…
2
10
31
2,653
So proud of our HouriganLab #ASH23 superstar abstract award winners - biostats PhD student ⁦@GegeGui0⁩ (oral on IDH2 MRD tomorrow Sun in sess617 at 9.30am and poster on IDH1 MRD on Mon) and medical student ⁦⁦@hegdepranay1⁩ presenting TKD MRD poster tomorrow (Sun).
1
3
52
3,567
She crushed it! First major international talk for ⁦@GegeGui0⁩ - biostatistics PhD student and key member of staff in Hourigan lab. The first, but not the last, time for her talking at ASH. ⁦@TheBethesdaLabs⁩ ⁦@CIBMTR⁩ ⁦@ASH_hematology⁩
1
8
60
3,587
Cleveland clinic medical student ⁦@ClevelandClinic⁩ ⁦@hegdepranay1⁩ presenting work he did on FLT3-TKD MRD during a MRSP year in our lab at ⁦@TheBethesdaLabs⁩ ⁦@NIH⁩ ⁦@CIBMTR⁩
8
1
38
3,264
Gege Gui retweeted
During #ASCO2022 , the AML Hub spoke with @DrChrisHourigan, @NIH. We asked, Can pre-transplant MRD testing predict patients who are more likely to relapse? 👉 loom.ly/DC-0-Fk 👈 #AML #AMLsm #leusm #leukemia
5
11
AML MRD Testing By NGS Identifies Adults At High Relapse Risk After Allogeneic Transplantation | ASH Clinical News | American Society of Hematology ashpublications.org/ashclini…
1
14
1
58
MRD in AML was previously most useful for papers, not patients. Until now! @DrChrisHourigan moving us into the “getting stuff done era” with this Herculean 1075 pt study of MRD in CR1 heading to SCT. #ASCO #leusm
9
37
Excited for @DrChrisHourigan to present our latest results tomorrow at 11:45AM CT from the Pre-MEASURE study at #ASCO2022 examining #MRD in a large cohort of #AML patients prior to transplant. Stick around for the last session! #savingthebest4last https://teapawt.net/t.co/LKY6ITj7gS
1
4
24
Gege Gui retweeted
CONGRESS #ASCO22 | @DrChrisHourigan @NIH discusses MRD testing prior to allo-SCT for pts with AML in first remission in the Pre-MEASURE study. (N=457). NGS-MRD prior to alloHCT in AML CR1 was prognostic. #leusm #leukemia
1
11
39
From the July issue: Personalized Single-Cell Proteogenomics to Distinguish Acute Myeloid #Leukemia from Nonmalignant #ClonalHematopoiesis. #leusm #singlecell @nih_nhlbi @LauraWDillon @DrChrisHourigan https://teapawt.net/t.co/lIvVXZjpeJ
7
1
12
Excited to share our work @Meg_Goswami Grateful for all the support from co-authors and especially our brilliant and caring mentor @DrChrisHourigan
Replying to @DrChrisHourigan
I’m so proud of @Meg_Goswami and @GegeGui0 for this work. While this was only a small clinical trial they have shown with their strong logic and beautiful science that in AML patients there was no evidence that adding anti-PD1 treatment to HMA resulted in additional benefit.
7
Personalized Single-Cell Proteogenomics to Distinguish Acute Myeloid Leukemia from Nonmalignant Clonal Hematopoiesis bloodcancerdiscov.aacrjourna…
New preprint from houriganlab.com @TheBethesdaLabs We are obsessed with MEASURABLE residual disease in AML, the idea that with higher sensitivity tools we can get better sense of leukemic burden and relapse risk for individuals in “remission”.
4
22
1
82
Summary of pre-alloHCT NGS testing in MDS and AML cohorts of @BMTCTN 0901 clinical trial from @TheBethesdaLabs @GegeGui0 @LauraWDillon Measurable Residual Disease Before Reduced-Intensity Allogeneic Transplantation in Patients With Myeloid Malignancy. ascopubs.org/doi/abs/10.1200…
10
29
Spending weekend preparing my talk for big pre-tenure external review. Reflecting how proud I am of amazing work my team at houriganlab.com has done over past four years despite Covid19. Fifty publications. Two plenary + 40 other talks. 8 awards. Great post-lab jobs.
8
4
1
62
New results from the @BMT_CTN 0901 trial and @TheBethesdaLabs @nih_nhlbi: The Impact Of Conditioning Intensity And Genomics On Relapse After Allogeneic Transplantation For Patients W/ Myelodysplastic Syndrome fal.cn/3dAoo #jcopo
6
18